Current status of immunological approaches for the treatment of prostate cancer

Current Opinion in Urology

Volumn 22, Issue 3, 2012, Pages 197-202

  Drake, Charles G ^a   Antonarakis, Emmanuel S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

immune checkpoints; immunotherapy; prostate cancer; T cell; vaccine

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; CANCER VACCINE; DNA VACCINE; DOCETAXEL; FLUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; KETOCONAZOLE; MONOCLONAL ANTIBODY J591; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T;

ANDROGEN DEPRIVATION THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); DNA IMMUNIZATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HUMAN; MELANOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SURVIVAL TIME; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; TISSUE EXTRACTS; TREATMENT OUTCOME;

EID: 84859632303     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3283519ad5     Document Type: Review

References (31)

1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422. The pivotal phase III trial leading to FDA approval of sipuleucel-T.
2. Palucka AK, Laupeze B, Aspord C, et al. Immunotherapy via dendritic cells. Adv Exp Med Biol 2005; 560:105-114.
3. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10:580-593.
4. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005.
5. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
6. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663-674. An elegant demonstration that immunotherapy for prostate cancer appears to be more effective in less aggressive disease.
7. Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012; 109:32-39.
8. Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2008; 179:S53-S59. (Pubitemid 351492526)
9. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007; 12:4957-4971.
10. Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005; 7:239-249. (Pubitemid 40568683)
11. Koh YT, Gray A, Higgins SA, et al. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 2009; 69:571-584. An important preclinical study underlining the potential importance of the relative sequencing of androgen ablation and immunotherapy.
12. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001; 98:14565-14570. (Pubitemid 33121432)
13. Gannon PO, Poisson AO, Delvoye N, et al. Characterization of the intraprostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009; 348:9-17.
14. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010; 37:533-546.
15. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37:430-439.
16. Hodi FS, O'Day SJ, McDermott DF, et al. Improved Survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723. The pivotal phase III trial leading to FDA approval of Ipilimumab.
17. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011; 17:6958-6962.
18. Beer TM, Slovin SF, Higano CS, et al. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol 2008; 26:5004.
19. Granberg C, Thompson RH, Quevedo JF, et al. Down-staging of locally advanced prostate cancer with anti-CTLA-4 monoclonal antibody prior to radical prostatectomy. J Clin Oncol 2009; 27:16103. An interesting study of Ipilimumab in the neoadjuvant setting.
20. Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009; 18:1001-1011.
21. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol 2010; 28:1099-1105. Demonstrates a potential survival advantage for men treated with ProstVac-VF as compared with placebo.
22. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001. (Pubitemid 351872317)
23. Alam S, McNeel DG. DNA vaccines for the treatment of prostate cancer. Expert Rev Vaccines 2010; 9:731-745.
24. McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer. J Clin Oncol 2009; 27:425-430.
25. Small EJ, Reese DM, Um B, et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999; 5:1738-1744. (Pubitemid 29334454)
26. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-327.
27. Tagawa ST, Beltran H, Vallabhajosula S, et al. Antiprostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010; 116:1075-1083. A comprehensive review of anti-PSMA antibody therapy for prostate cancer.
28. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23:4591-4601. (Pubitemid 46224061)
29. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520. (Pubitemid 39315318)
30. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512. (Pubitemid 39315317)
31. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29:3651-3658.